Cargando…
Cardiomyopathic troponin mutations predominantly occur at its interface with actin and tropomyosin
Reversible Ca(2+) binding to troponin is the primary on-off switch of the contractile apparatus of striated muscles, including the heart. Dominant missense mutations in human cardiac troponin genes are among the causes of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. Structural under...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836260/ https://www.ncbi.nlm.nih.gov/pubmed/33492345 http://dx.doi.org/10.1085/jgp.202012815 |
_version_ | 1783642709866577920 |
---|---|
author | Tobacman, Larry S. Cammarato, Anthony |
author_facet | Tobacman, Larry S. Cammarato, Anthony |
author_sort | Tobacman, Larry S. |
collection | PubMed |
description | Reversible Ca(2+) binding to troponin is the primary on-off switch of the contractile apparatus of striated muscles, including the heart. Dominant missense mutations in human cardiac troponin genes are among the causes of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. Structural understanding of troponin action has recently advanced considerably via electron microscopy and molecular dynamics studies of the thin filament. As a result, it is now possible to examine cardiomyopathy-inducing troponin mutations in thin-filament structural context, and from that to seek new insight into pathogenesis and into the troponin regulatory mechanism. We compiled from consortium reports a representative set of troponin mutation sites whose pathogenicity was determined using standardized clinical genetics criteria. Another set of sites, apparently tolerant of amino acid substitutions, was compiled from the gnomAD v2 database. Pathogenic substitutions occurred predominantly in the areas of troponin that contact actin or tropomyosin, including, but not limited to, two regions of newly proposed structure and long-known implication in cardiomyopathy: the C-terminal third of troponin I and a part of the troponin T N terminus. The pathogenic mutations were located in troponin regions that prevent contraction under low Ca(2+) concentration conditions. These regions contribute to Ca(2+)-regulated steric hindrance of myosin by the combined effects of troponin and tropomyosin. Loss-of-function mutations within these parts of troponin result in loss of inhibition, consistent with the hypercontractile phenotype characteristic of HCM. Notably, pathogenic mutations are absent in our dataset from the Ca(2+)-binding, activation-producing troponin C (TnC) N-lobe, which controls contraction by a multi-faceted mechanism. Apparently benign mutations are also diminished in the TnC N-lobe, suggesting mutations are poorly tolerated in that critical domain. |
format | Online Article Text |
id | pubmed-7836260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-78362602021-09-01 Cardiomyopathic troponin mutations predominantly occur at its interface with actin and tropomyosin Tobacman, Larry S. Cammarato, Anthony J Gen Physiol Article Reversible Ca(2+) binding to troponin is the primary on-off switch of the contractile apparatus of striated muscles, including the heart. Dominant missense mutations in human cardiac troponin genes are among the causes of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy. Structural understanding of troponin action has recently advanced considerably via electron microscopy and molecular dynamics studies of the thin filament. As a result, it is now possible to examine cardiomyopathy-inducing troponin mutations in thin-filament structural context, and from that to seek new insight into pathogenesis and into the troponin regulatory mechanism. We compiled from consortium reports a representative set of troponin mutation sites whose pathogenicity was determined using standardized clinical genetics criteria. Another set of sites, apparently tolerant of amino acid substitutions, was compiled from the gnomAD v2 database. Pathogenic substitutions occurred predominantly in the areas of troponin that contact actin or tropomyosin, including, but not limited to, two regions of newly proposed structure and long-known implication in cardiomyopathy: the C-terminal third of troponin I and a part of the troponin T N terminus. The pathogenic mutations were located in troponin regions that prevent contraction under low Ca(2+) concentration conditions. These regions contribute to Ca(2+)-regulated steric hindrance of myosin by the combined effects of troponin and tropomyosin. Loss-of-function mutations within these parts of troponin result in loss of inhibition, consistent with the hypercontractile phenotype characteristic of HCM. Notably, pathogenic mutations are absent in our dataset from the Ca(2+)-binding, activation-producing troponin C (TnC) N-lobe, which controls contraction by a multi-faceted mechanism. Apparently benign mutations are also diminished in the TnC N-lobe, suggesting mutations are poorly tolerated in that critical domain. Rockefeller University Press 2021-01-25 /pmc/articles/PMC7836260/ /pubmed/33492345 http://dx.doi.org/10.1085/jgp.202012815 Text en © 2021 Tobacman and Cammarato http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Article Tobacman, Larry S. Cammarato, Anthony Cardiomyopathic troponin mutations predominantly occur at its interface with actin and tropomyosin |
title | Cardiomyopathic troponin mutations predominantly occur at its interface with actin and tropomyosin |
title_full | Cardiomyopathic troponin mutations predominantly occur at its interface with actin and tropomyosin |
title_fullStr | Cardiomyopathic troponin mutations predominantly occur at its interface with actin and tropomyosin |
title_full_unstemmed | Cardiomyopathic troponin mutations predominantly occur at its interface with actin and tropomyosin |
title_short | Cardiomyopathic troponin mutations predominantly occur at its interface with actin and tropomyosin |
title_sort | cardiomyopathic troponin mutations predominantly occur at its interface with actin and tropomyosin |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836260/ https://www.ncbi.nlm.nih.gov/pubmed/33492345 http://dx.doi.org/10.1085/jgp.202012815 |
work_keys_str_mv | AT tobacmanlarrys cardiomyopathictroponinmutationspredominantlyoccuratitsinterfacewithactinandtropomyosin AT cammaratoanthony cardiomyopathictroponinmutationspredominantlyoccuratitsinterfacewithactinandtropomyosin |